Literature DB >> 2925748

Does myeloma secrete an osteoblast inhibiting factor?

C E Evans1, C S Galasko, C Ward.   

Abstract

Unlike most other tumours, myeloma causes bone destruction without an osteoblastic reaction; we tried to assess whether myeloma secretes a humoral factor that inhibits osteoblasts. Human bone-derived cells were either co-cultured with myeloma cells, or cultured in medium conditioned by myeloma cells. Bone-derived cell growth was measured by cell counts and by uptake of tritiated thymidine (3H-Tdr); growth was inhibited when cultured in medium conditioned by myeloma cells and some inhibition was seen when the bone-derived cells were co-cultured with myeloma cells. The inhibiting effect was dose-dependent and also dependent upon the density of the myeloma cells conditioning the medium. The results of our study suggest that myeloma secretes an osteoblast inhibiting factor of less than 50,000 Dalton molecular weight.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2925748     DOI: 10.1302/0301-620X.71B2.2925748

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  11 in total

1.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

Review 2.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 3.  Tumor-host cell interactions in the bone disease of myeloma.

Authors:  Jessica A Fowler; Claire M Edwards; Peter I Croucher
Journal:  Bone       Date:  2010-07-13       Impact factor: 4.398

Review 4.  The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.

Authors:  E V McCloskey; J F Guest; J A Kanis
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease.

Authors:  Bruce P Ayati; Claire M Edwards; Glenn F Webb; John P Wikswo
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

6.  Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.

Authors:  Claire M Edwards; James R Edwards; Seint T Lwin; Javier Esparza; Babatunde O Oyajobi; Brandon McCluskey; Steven Munoz; Barry Grubbs; Gregory R Mundy
Journal:  Blood       Date:  2007-12-19       Impact factor: 22.113

Review 7.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

8.  Myeloma affects both the growth and function of human osteoblast-like cells.

Authors:  C E Evans; C Ward; L Rathour; C B Galasko
Journal:  Clin Exp Metastasis       Date:  1992-01       Impact factor: 5.150

Review 9.  Osteoblastogenesis and tumor growth in myeloma.

Authors:  Shmuel Yaccoby
Journal:  Leuk Lymphoma       Date:  2010-02

10.  Lead exposure inhibits fracture healing and is associated with increased chondrogenesis, delay in cartilage mineralization, and a decrease in osteoprogenitor frequency.

Authors:  Jonathan J Carmouche; J Edward Puzas; Xinping Zhang; Prarop Tiyapatanaputi; Deborah A Cory-Slechta; Robert Gelein; Michael Zuscik; Randy N Rosier; Brendan F Boyce; Regis J O'Keefe; Edward M Schwarz
Journal:  Environ Health Perspect       Date:  2005-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.